[1] J.L. Ferguson, S.P. Turner, Bone cancer: diagnosis and treatment principles, American family physician, 98 (2018) 205-213. [2] P. Whig, B.Y. Kasula, N. Yathiraju, A. Jain, S. Sharma, Bone cancer classification and detection using machine learning technique, in: Diagnosing Musculoskeletal Conditions using Artifical Intelligence and Machine Learning to Aid Interpretation of Clinical Imaging, Elsevier, 2025, pp. 65-80. [3] D. Tsvetkova, S. Ivanova, Application of approved cisplatin derivatives in combination therapy against different cancer diseases, Molecules, 27 (2022) 2466. [4] R. Hayward, D.S. Hydock, Doxorubicin cardiotoxicity in the rat: an in vivo characterization, Journal of the American Association for Laboratory Animal Science, 46 (2007) 20-32. [5] M. Sohail, Z. Sun, Y. Li, X. Gu, H. Xu, Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy, Expert review of anticancer therapy, 21 (2021) 1385-1398. [6] S. Sritharan, N. Sivalingam, A comprehensive review on time-tested anticancer drug doxorubicin, Life sciences, 278 (2021) 119527. [7] O. Tacar, P. Sriamornsak, C.R. Dass, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems, Journal of pharmacy and pharmacology, 65 (2013) 157-170. [8] A. Berdiaki, M. Neagu, E.-M. Giatagana, A. Kuskov, A.M. Tsatsakis, G.N. Tzanakakis, D. Nikitovic, Glycosaminoglycans: Carriers and targets for tailored anti-cancer therapy, Biomolecules, 11 (2021) 395. [9] K.d.A. Mesquita, Role of mitochondria and DNA damage responses in cancer stem cells resistance to chemotherapy, in, 2016. [10] S. Ingole, N. Vasdev, M. Tekade, T. Gupta, B. Pawar, M. Mhatre, A.G. Prasad, R.K. Tekade, Toxic effects of cancer therapies, in: Public Health and Toxicology Issues Drug Research, Volume 2, Elsevier, 2024, pp. 353-379. [11] U. Anand, A. Dey, A.K.S. Chandel, R. Sanyal, A. Mishra, D.K. Pandey, V. De Falco, A. Upadhyay, R. Kandimalla, A. Chaudhary, Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics, Genes & diseases, 10 (2023) 1367-1401. [12] A. Bisht, D. Avinash, K.K. Sahu, P. Patel, G. Das Gupta, B.D. Kurmi, A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer, Drug Delivery and Translational Research, 15 (2025) 102-133. [13] M.L. Tan, P.F. Choong, C.R. Dass, Doxorubicin delivery systems based on chitosan for cancer therapy, Journal of Pharmacy and Pharmacology, 61 (2009) 131-142. [14] R. Biswas, S. Mondal, M.A. Ansari, T. Sarkar, I.P. Condiuc, G. Trifas, L.I. Atanase, Chitosan and its derivatives as nanocarriers for drug delivery, Molecules, 30 (2025) 1297. [15] F. Migliorini, G. La Padula, E. Torsiello, F. Spiezia, F. Oliva, N. Maffulli, Strategies for large bone defect reconstruction after trauma, infections or tumour excision: a comprehensive review of the literature, European journal of medical research, 26 (2021) 1-10. [16] J. Zhang, W. Zhang, W. Yue, W. Qin, Y. Zhao, G. Xu, Research Progress of Bone Grafting: A Comprehensive Review, International Journal of Nanomedicine, (2025) 4729-4757. [17] R.R. Betz, Limitations of autograft and allograft: new synthetic solutions, Orthopedics, 2025 (02S561-S570). [18] X. Wang, S. Xu, S. Zhou, W. Xu, M. Leary, P. Choong, M. Qian, M. Brandt, Y.M. Xie, Topological design and additive manufacturing of porous metals for bone scaffolds and orthopaedic implants: A review, Biomaterials, 83 (2016) 127-141. [19] K. Gupta, K. Meena, Artificial bone scaffolds and bone joints by additive manufacturing: A review, Bioprinting, 31 (2023) e00268. [20] A. Bandyopadhyay, I. Mitra, J.D. Avila, M. Upadhyayula, S. Bose, Porous metal implants: processing, properties, and challenges, International Journal of Extreme Manufacturing, 5 (2023) 032014. [21] N. Koju, S. Niraula, B. Fotovvati, Additively manufactured porous Ti6Al4V for bone implants: a review, Metals, 12 (2022) 687. [22] R. Shukla, M.K. Yadav, L.Y.C. Madruga, J. Jayaraj, K. Popat, Z. Wang, L. Xi, K.G. Prashanth, A novel Ti-eggshell-based composite fabricated by combined additive manufacturing-powder metallurgical routes as bioimplants, Ceramics International, 51 (2025) 6281-6291. [23] M.-M. Germaini, S. Belhabib, S. Guessasma, R. Deterre, P. Corre, P. Weiss, Additive manufacturing of biomaterials for bone tissue engineering–A critical review of the state of the art and new concepts, Progress in Materials Science, 130 (2022) 100963. [24] T. Hanawa, Biocompatibility of titanium from the viewpoint of its surface, Science and Technology of Advanced Materials, 23 (2022) 457-472. [25] S.R. Paital, N.B. Dahotre, Calcium phosphate coatings for bio-implant applications: Materials, performance factors, and methodologies, Materials Science and Engineering: R: Reports, 66 (2009) 1-70. [26] P.P. Mahamuni-Badiger, P.M. Patil, M.V. Badiger, P.R. Patel, B.S. Thorat-Gadgil, A. Pandit, R.A. Bohara, Biofilm formation to inhibition: Role of zinc oxide-based nanoparticles, Materials Science and Engineering: C, 108 (2020) 110319. [27] C. Pushpalatha, J. Suresh, V. Gayathri, S. Sowmya, D. Augustine, A. Alamoudi, B. Zidane, N.H. Mohammad Albar, S. Patil, Zinc oxide nanoparticles: a review on its applications in dentistry, Frontiers in bioengineering and biotechnology, 10 (2022) 917990. [28]. Z. Wang, Y. Duan, Y. Duan, Application of polydopamine in tumor targeted drug delivery system and its drug release behavior, Journal of Controlled Release, 290 (2018) 56-74. [29] Y. Yuan, B. Guo, L. Hao, N. Liu, Y. Lin, W. Guo, X. Li, B. Gu, Doxorubicin-loaded environmentally friendly carbon dots as a novel drug delivery system for nucleus targeted cancer therapy, Colloids and Surfaces B: Biointerfaces, 159 (2017) 349-359. [30] W. Arap, R. Pasqualini, E. Ruoslahti, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science, 279 (1998) 377-380. [31] S. Chen, H. Lan, M. Liu, C. He, Q. Li, S. Zheng, Y. Zheng, Z. Wu, T. Liu, B. Zhao, Less is More: Biomimetic Hybrid Membrane Nanocarriers for Highly Efficient Tumor Targeted Drug Delivery, Small, (2025) 2407245. [32] Y.-L. Lai, Y.-M. Cheng, S.-K. Yen, Doxorubicin-chitosan-hydroxyapatite composite coatings on titanium alloy for localized cancer therapy, Materials Science and Engineering: C, 104 (2019) 109953. [33] M. Sumathra, M. Rajan, R. Amarnath Praphakar, N. Marraiki, A.M. Elgorban, In vivo assessment of a hydroxyapatite/κ-carrageenan–maleic anhydride–casein/doxorubicin composite-coated titanium bone implant, ACS Biomaterials Science & Engineering, 6 (2020) 1650-1662. [34] N. Karimi, M. Atapour, A. Taherizadeh, B. Ercan, M. Galati, A. Saboori, Surface functionalization of additively manufactured Ti6Al4V scaffolds with CaP/ZnO coatings, Progress in Additive Manufacturing, 2-10, (2025). [35] L. Bacakova, E. Filova, M. Parizek, T. Ruml, V. Svorcik, Modulation of cell adhesion, proliferation and differentiation on materials designed for body implants, Biotechnology advances, 29 (2011) 739-767. [36] B. Boyan, A. Cheng, R. Olivares-Navarrete, Z. Schwartz, Implant surface design regulates mesenchymal stem cell differentiation and maturation, Advances in dental research, 28 (2016) 10-17. [37] L.P. Mocanu, Influence of powder reuse on metallurgical and mechanical properties of Ti-6Al-4V EB-PBF manufactured components, 2024. [38] A. Raza, Powder degradation during powder bed fusion processing, Chalmers Tekniska Hogskola, 2021. [39] Y. Jiang, T. Jia, W. Gong, P.H. Wooley, S.-Y. Yang, Titanium particle-challenged osteoblasts promote osteoclastogenesis and osteolysis in a murine model of periprosthestic osteolysis, Acta biomaterialia, 9 (2013) 7564-7572. [40] A. Kiani, F. Davar, M. Bazarganipour, Influence of verjuice extract on the morphology, phase, and magnetic properties of green synthesized CoFe2O4 nanoparticle: its application as an anticancer drug delivery, Ceramics International, 48 (2022) 34895-34906. [41] J. Vecstaudza, M. Gasik, J. Locs, Amorphous calcium phosphate materials: Formation, structure and thermal behaviour, Journal of the European Ceramic Society, 39 (2019) 1642-1649. [42]. A. Boyd, G. Burke, H. Duffy, M. Cairns, P. O’Hare, B. Meenan, Characterisation of calcium phosphate/titanium dioxide hybrid coatings, Journal of Materials Science: Materials in Medicine, 19 (2008) 485-498. [43] O. Oleshko, Y. Husak, V. Korniienko, R. Pshenychnyi, Y. Varava, O. Kalinkevich, M. Pisarek, K. Grundsteins, O. Pogorielova, O. Mishchenko, Biocompatibility and antibacterial properties of zno-incorporated anodic oxide coatings on TiZrNb alloy, Nanomaterials, 10 (2020) 2401. [44] K. Kubiak, M. Wilson, T. Mathia, P. Carval, Wettability versus roughness of engineering surfaces, Wear, 271 (2011) 523-528. [45] A. AlRatrout, M.J. Blunt, B. Bijeljic, Wettability in complex porous materials, the mixed-wet state, and its relationship to surface roughness, Proceedings of the National Academy of Sciences, 115 (2018) 8901-8906. [46] D.P. Papazoglou, L. Hobbs, Y. Sun, A. Neidhard-Doll, In Vitro Proliferation of MG-63 Cells in Additively Manufactured Ti-6Al-4V Biomimetic Lattice Structures with Varying Strut Geometry and Porosity, Materials, 17 (2024) 4608. [47] M. Mailland, R. Waelchli, M. Ruat, H.G. Boddeke, K. Seuwen, Stimulation of cell proliferation by calcium and a calcimimetic compound, Endocrinology, 138 (1997) 3601-3605. [48] A. Bandyopadhyay, E.A. Withey, J. Moore, S. Bose, Influence of ZnO doping in calcium phosphate ceramics, Materials Science and Engineering: C, 27 (2007) 14-17. [49] H. Zhu, S. Sarkar, L. Scott, I. Danelisen, M.A. Trush, Z. Jia, Y.R. Li, Doxorubicin redox biology: redox cycling, topoisomerase inhibition, and oxidative stress, Reactive oxygen species (Apex, NC), 1 (2016) 189. [50] S. Ghosh, R.S.K. Raju, N. Ghosh, K. Chaudhury, S. Ghosh, I. Banerjee, N. Pramanik, Development and physicochemical characterization of doxorubicin-encapsulated hydroxyapatite–polyvinyl alcohol nanocomposite for repair of osteosarcoma-affected bone tissues, Comptes Rendus Chimie, 22 (2019) 46-57. [51] M. Kciuk, A. Gielecińska, S. Mujwar, D. Kołat, Ż. Kałuzińska-Kołat, I. Celik, R. Kontek, Doxorubicin—an agent with multiple mechanisms of anticancer activity, Cells, 12 (2023) 659.